Affymax, Inc. is a biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2006-12-15. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The firm has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.
AFFY stock price ended at $0 on Cuma, after dropping NaN%
On the latest trading day Jun 19, 2026, the stock price of AFFY fell by NaN%, dropping from $NaN to $NaN. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $NaN and a high of $NaN. On the latest trading day, the trading volume for AFFY decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, -- shares were traded, with a market value of approximately --.
AFFYTeknik Sinyalleri
Teknik Sinyaller Özeti
Satın Alma Sinyalleri 0
Nötr Sinyaller 7
Satış Sinyalleri 0
Strong Sell
Sell
Neutral
Buy
Strong Buy
AFFY, şu anda 0 alım sinyali ve 0 satım sinyali vermektedir. Hisse senedi --'ten beri Aşağı yönlü trend durumundadır ve bu dönemde toplam -- fiyat değişimi gerçekleşti. Genel olarak teknik göstergeler orta vadeli olarak Neutral görünüm işaret etmektedir.
AFFY için Boğa/Ayı Sinyalleri
Hareketli ortalamalar, RSI, MACD ve işlem hacmi gibi temel göstergeleri analiz ederek AFFY için yükseliş ve düşüş sinyalleri üretiyoruz. Bu analizlerle daha bilinçli yatırım kararları verin.